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Abstract
Aims: This study aimed (1) to estimate the prevalence of prediabetes according to 
different definitions, (2) to evaluate regression to normal glucose levels and 
progression towards T2DM, and (3) to determine factors associated with regression 
and progression across four diverse geographical settings in a Latin American country.
Methods: The CRONICAS Cohort Study was conducted in four different areas in Peru. 
Enrollment started in September 2010 and follow-up was conducted in 2013. 
Prediabetes, T2DM and normal glucose levels were defined according to the World 
Health Organization (WHO), American Diabetes Association (ADA), and National 
Institute for Health and Care Excellence (NICE) definitions. The main outcomes were 
regression to normal glucose levels and incidence of T2DM. Prevalence estimates and 
95% confidence intervals (95% CI) were calculated. Crude and adjusted regression 
models using Poisson were performed and relative risk ratios (RRR) and 95% CI were 
calculated. 
Results: At baseline, the prevalence of prediabetes varied markedly by definition used: 
6.5%(95% CI 5.6% - 7.6%), 53.6%(95% CI 51.6% - 55.6%), and 24.6%(95% CI 22.8% 
- 26.4%) according to WHO, ADA and NICE criteria, respectively. After 2.2 years of 
follow-up, in those with prediabetes, the cumulative incidence of regression to 
euglycemia ranged between 31.4% and 68.9%, whereas the incidence of T2DM varied 
from 5.5% to 28.8%. Factors associated with regression to normal glucose levels and 
progression to diabetes were age, body mass index, and insulin resistance.
Conclusions: Regression from pre-diabetes back to euglycemia was much more 
common than progression to diabetes. 
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INTRODUCTION
The prevalence and incidence of type 2 diabetes mellitus (T2DM) has been increasing 
worldwide with a significant impact in low and middle income countries (LMIC) (1). 
Moreover, the total number of adults diagnosed with T2DM in the last 35 years has 
nearly quadrupled. The worldwide cost related to T2DM management and its 
complications ranges between 54,000 and 283,000 million USD (1, 2). Early diagnosis 
and detection of risk factors to prevent T2DM is crucial to control the epidemic. From 
a health system's perspective, particularly in LMIC settings, some challenges remain 
in clarifying the burden of T2DM due to the controversy generated by having different 
cut-offs for the definitions of diabetes and prediabetes, some of them also including 
glycated hemoglobin (3, 4).
The World Health Organization considers cases at risk for T2DM if the individuals have 
impaired fasting glucose (fasting plasma glucose between 110-125 mg/dL or 2-h 
plasma glucose 140–199 mg/dL (7.8–11.0 mmol/L)).(3) The American Diabetes 
Association (ADA) used the term “prediabetes” when fasting plasma glucose is 
between 100-125 mg/dL or glycated hemoglobin (HbA1c) is between 5.7% and 6.4% 
or 2-h plasma glucose 140–199 mg/dL (7.8–11.0 mmol/L),(4) whereas the 
International Expert Committee (IEC) (5) and the UK-based National Institute for 
Health and Clinical Excellence (NICE) (6) used HbA1c cut-offs between 6·0 and 6·4% 
to defined prediabetes. A meta-analysis reported that a level of HbA1c between 6.0 
and 6.4% slightly overestimates the risk of developing T2DM compared to WHO cut-
offs for impaired fasting glucose and impaired glucose tolerance (7). On the other 
hand, a more recent study comparing different T2DM definitions and using major 
clinical T2DM complications as outcomes, i.e. chronic kidney disease, cardiovascular 
disease, all-cause mortality, suggested that definitions using HbA1c were more 
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specific and provided modest improvements in risk discrimination for clinical 
complications in comparison to glucose definitions (8).
Chronic elevated blood glucose below the range of T2DM diagnosis represents a risk 
factor for cardiovascular disease and mortality (9). The proportion of progression of 
what is defined as “prediabetes” to T2DM remains unclear, however it has been 
described that up to 70% of prediabetes cases will eventually progress to T2DM, at a 
rate of 5% to 10% per year (10-12). Additionally, potential confounders such as body 
mass index, abdominal obesity, family history of T2DM, hypertension, cholesterol 
level, and low physical activity may potentially interfere with the progression from 
prediabetes to T2DM (11).
Some epidemiological studies, mostly conducted in high-income countries, have 
described that people with prediabetes may either progress towards T2DM or may 
regress to normal glucose levels each year as is described in 10% of the population 
(13, 14). A post hoc analysis of participants who attended to the Diabetes Prevention 
Program (DPP) found some factors at baseline related to regression to normal glucose 
levels, such as lower fasting plasma glucose, greater insulin secretion, younger age, 
weight loss and after the intervention the intensive lifestyle was associated to 
regression (15). Later on, the DPP Outcomes Study (DPPOS) found higher β–cell 
function and insulin sensitivity associated with regression to normal glucose levels 
(16), as was also body mass index (14). In addition, some pharmacological agents 
have been used to promote regression to normal glucose levels through reduction of 
risk factors; for example Lorcaserin, a selective 5HT2C receptor agonist, has been 
associated with weight loss and a decrease of HbA1c after two months (17). Moreover, 
pharmacologic combinations using insulin sensitizers including pioglitazone, 
exenatide and metformin have shown to promote regression to euglycemia in those 
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with impaired fasting glucose and impaired glucose tolerance in a greater proportion 
compared to those receiving only life style recommendations (18). Also, a recent study 
found effectiveness of early interventions based on a personalized medicine approach 
(13, 18).
Studies of progression towards T2DM or regression to normal glucose levels among 
people with prediabetes are scarce in LMIC and regression to the mean may introduce 
further methodological challenges to study this phenomenon. Despite of most of T2DM 
cases are reported in these countries, associated factors for progression and 
regression are not fully studied. Therefore, this study aimed to: (1) to estimate the 
prevalence of prediabetes according to different definitions, (2) to evaluate regression 
to normal glucose levels and progression towards T2DM independent from regression 
to the mean effects, and (3) to determine factors associated with regression to normal 
glucose levels and progression to diabetes across four diverse geographical settings 
in a Latin American country.
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METHODS
Study design, settings and participants
Enrollment started in September 2010 and follow-up was conducted, on average, 2.2 
years after initial assessment. The CRONICAS Cohort Study was conducted in three 
different cities and from different areas: Pampas de San Juan de Miraflores, a highly 
urbanized community located in Lima, the capital city of Peru; Tumbes, a semi-urban 
city located on the northern coast of Peru; and Puno, located 3825 meters above sea 
level, where urban and rural communities were enrolled.
All participants were 35 years or older, full-time residents in the study area, and 
provided informed consent. Potential participants were excluded if they were pregnant, 
had any physical disability preventing clinical measurements, and had active 
pulmonary tuberculosis. Sex and age strata (35-44, 45-54, 55-64, and ≥65 years) were 
pre-defined, and participants were selected through a random sampling technique 
using the most updated census available in each study site. Only one participant per 
household were invited into the study. In Puno, recruitment was stratified to include 
500 participants each from the urban and rural settings (19).
Procedures
Fieldwork activities and procedures of the CRONICAS Cohort Study have been 
described in detail elsewhere (19). Fieldworkers were trained to apply face-to-face 
questionnaires to participants using paper-based formats, and to perform clinical 
evaluation procedures. After completing the questionnaire, an appointment for a 
clinical assessment was arranged to ensure an adequate fasting period (between 8 
and 12 hours). A total of 13.5 ml of blood was drawn according to the laboratory 
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analysis which included serum insulin, plasma glucose and HbA1C. Serum glucose 
was measured using an enzymatic colorimetric method (GOD-PAP; Modular P-
E/Roche-Cobas, Grenzach-Whylen, Germany) and HbA1c was measured using high-
performance liquid chromatography (HPLC, D10-BIORAD, Germany), which is 
traceable to the Diabetes Control and Complications Trials reference study as certified 
by the National Glycohemoglobin Standardization Program. In addition, serum insulin 
was measured using electrochemiluminescence (Modular P-E/Roche- Cobas). 
The clinical assessment included measurement of standing height, weight and blood 
pressure using standardized techniques(19) and the following equipment: TANITA 
TBF-300A body composition analyzer and an automatic monitor OMRON HEM-780 
(20). In the case of blood pressure, measurements were obtained by triplicate, after a 





We considered at baseline the definitions for prediabetes recognized by WHO (i.e. 
impaired fasting glucose),(3) fasting glucose concentration cut-off 110-125 mg/dL 
(6·1–6·9 mmol/L); along with definitions recommended by the ADA (4): fasting glucose 
concentration cut-off 100-125 mg/dL (5·6–6·9 mmol/L) or HbA1c cut-off 5·7–6·4% (39–
46 mmol/mol), and that of IEC and NICE (HbA1c cut-off 6·0–6·4% [42–46 mmol/mol]) 
(5). The 2-h plasma glucose values of 140–199 mg/dL (7.8–11.0 mmol/L) is included 
in WHO and ADA definitions but not measured in the current study because the 
CRONICAS Cohort was design to measure the incidence of cardiovascular risk factors 
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in three different Peruvian regions. The original protocol of this study did not include 
this test in their baseline evaluation due to logistical limitations, particularly in rural 
areas, and budget restrictions. 
All laboratory results were provided in print to the study participants and they were 
advised, at baseline, to seek further care if they had diabetes, hypertension or any 
dyslipidemia.
b) Outcomes
The main outcomes were T2DM and normal glucose levels measured at follow-up. 
Each outcome was defined using the WHO, ADA and NICE definitions described in 
the Table 1. Also, we included participants that self reported diabetes diagnoses by a 
health worker and received treatment for diabetes.
Co-variates 
We considered some additional variables and confounders of importance for the study, 
assessed at baseline of the study:
First, we considered site. Using the same definition of CRONICAS Cohort Study, a 
total of 4 sites were defined in 3 cities in Peru according to urbanicity levels. Thus, 
Lima, highly urbanized site located on the coast; Tumbes, semi-urban located on the 
coast; and Urban Puno and rural Puno, both located in the highlands, were 
considered. 
Other characteristics of the study participants included in the analysis were 
demographic variables such as sex, age (in four categories: 35 to 44, 45 to 54, 55 to 
64 and ≥ 65 years old), educational level (<7 years [less than secondary school], 7–
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11 years [any/completed secondary school] and ≥12 years [more than secondary 
school]), and socio-economic status (assessed through a wealth index indicator based 
on assets possession and household facilities, and then categorized in tertiles for 
analysis) (21). Lifestyle habits were also evaluated, including current daily smoking 
(self-report of smoking at least one cigarette per day); hazardous drinking (if the 
participant had a score ≥8 using the Alcohol Use Disorder Identification Test) (22); and 
physical activity levels, measured using both the leisure time and transportation-
related domains of the International Physical Activity Questionnaire (IPAQ) and then 
classified as high/moderate vs. low physical activity according to the definition of the 
questionnaire. 
Anthropometric and clinical covariates were also explored. Body mass index (BMI) 
was included and categorized as normal (≥18.5 to <25 kg/m2), overweight (≥25 to <30 
kg/m2), or obese (≥30 kg/m2). Hypertension was defined as systolic blood pressure 
(SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg, according to the 
results obtained after calculating the average of the second and third blood pressure 
measurements. We also considered, at baseline, the self-report of physician diagnosis 
or use of antihypertensive medication. HOMA-IR was calculated with the formula 
developed by Matthews (23) and categorized in two groups (<3 and ≥ 3) to assess 
insulin resistance (24). Another variable of interest was family history of diabetes 
defined by the self-report of T2DM diagnosis of one of the participant’s parents. 
Sample Size
As this is a secondary analysis of the original cohort (19), we conducted post-hoc 
power calculations. The literature describes that between 10% and 50% of the 
population have prediabetes, depending on the definition used (25, 26). We expected 
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to have approximately from 234 (10%) to 1172 (50%) individuals with prediabetes 
among participants of the CRONICAS Cohort Study. Considering that 5 to 10% of 
people with prediabetes progress each year to diabetes (12), our study sample of 234 
and 1172 individuals with prediabetes had ≥ 80% power to find the expected incidence 
rate.
Statistical analysis 
All statistical analyses were performed using Stata 12.0 (Stata Corp, College Station, 
TX, USA). Using baseline data, prevalence of prediabetes and 95% confidence 
intervals (95% CI) were estimated according to each definition, as previously 
described.
After excluding cases of T2DM diagnosed at baseline, the cumulative incidence of 
progression from prediabetes towards T2DM and that of regression to normal glucose 
levels were calculated using information at 2.2 years of follow-up. 
Finally, among participants with prediabetes, crude and adjusted Poisson regression 
models were created to determine factors associated with regression to normal 
glucose levels and progression towards diabetes. Relative risk ratios (RRR) and 95% 
CI were reported for crude analysis, where a RRR >1 implied greater probability to 
regress to normal glucose levels or progress towards diabetes, and when the RRR 
was <1, the factor reduced the probability to regress to normal glucose levels (i.e. 
more risk to remain in the prediabetes category or T2DM at follow-up) or the factor 
reduced the probability to progress to diabetes (i.e. more risk to remain in the 
prediabetes category or normal glucose levels at follow-up). Adjusted models included 
variables assessed at baseline like: age, sex, site, education level, BMI, HOMA index 
and hypertension. The selection criteria to included variables in the model were 
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performed according to theory and not statistical methods. Given the multiple 
comparisons, Bonferroni adjustment of critical p-value was used adjusting for 9 test as 
9 variables considered 0.05/9= 0.006 (p<0.006) and adjusted models were reported 
with 99.4% CI.
Additionally, we explored regression to the mean in glucose and HbA1c levels. 
“Regression to the mean is a statistical phenomenon that can make natural variation 
in repeated data look like real change”.(23) For these reason we evaluated the 
potential effects of it on our estimates using the formula of Barnett AG et al (27) for 
each cut off point of glucose and HbA1c. 
Ethics
The Institutional Review Boards of Universidad Peruana Cayetano Heredia and 
Asociacion Benefica PRISMA, both in Lima, Peru, and Johns Hopkins University in 
Baltimore, US, approved the study. Participants received information about objectives 
and procedures of the study and gave oral consent due to high rates of illiteracy, 
mainly in rural and semi-urban areas. 
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RESULTS
Characteristics of study participants
A total of 3140 participants from the CRONICAS Cohort Study had a complete 
baseline assessment including questionnaire, clinical measurements and blood 
samples. At the 2.2yr follow-up (SD 0.7, minimum 0.5 and maximum 4 years), 2879 
subjects were at-risk to develop diabetes over follow-up (Figure 1), and those who did 
not provide a blood sample for the glucose test were excluded. Hence, a total of 2345 
participants were included in the analysis (Supplementary material 1).
At baseline, the participant’s mean age was 54.3 years (SD ±12.5). The proportion of 
females was slightly higher (50.7%) and nearly the half of the sample (42.2%) had an 
education level less than 7 years. The distribution of participants between sites was 
36.3% in Lima, 34.6% in Tumbes, 15.6% in urban Puno, and 13.5% in rural Puno. The 
overall prevalence of risk factors related to T2DM including overweight, obesity, 
hypertension and insulin resistance at baseline were 45.6%, 27.1%, 17.6% and 22.1% 
respectively. 
Prediabetes at baseline
The prevalence of prediabetes at baseline varied by the definition used, it was 6.5% 
(95% CI 5.6% - 7.6%), 53.6% (95% CI 51.6% - 55.6%), and 24.6% (95% CI 22.8 – 26. 
4%) according to WHO, ADA and, NICE and criteria. Only 61 (2.6%) participants had 
prediabetes considering the three definitions.
Regression to normal glucose levels at 2.2 years from prediabetes at baseline 
The cumulative incidence of regression to normal glucose levels at 2.2 years was 
49.7% (95% CI 41.5% – 57.9%) according to WHO, 31.4% (95% CI 28.8% – 34.0%) 
according to ADA, and 68.9% (95% CI 65.0% – 72.7%) according to NICE.
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Incidence of T2DM at 2.2 years according to prediabetes definition
Among participants with prediabetes, the cumulative T2DM incidence at 2.2 years was 
28.8% (95% CI 21.7% – 36.6%) using the WHO definition, whereas using ADA and 
NICE definitions, only 9.4% (95% CI 7.8% – 11.1%) and 5.5% (95% CI 3.8% – 7.7%), 
respectively, progressed to T2DM (Table 2).
On the other hand, the group with normal glucose levels at baseline had a cumulative 
T2DM incidence at 2.2 years of 3.5% (95% CI 2.7% – 4.3%), 2.3% (95% CI 1.5% – 
3.4%) and 3.3% (95% CI 2.5% – 4.2%) using WHO, ADA, and NICE definitions 
correspondingly (Table 2). 
Regression to the mean
The estimation of regression to the mean was performed. In the case of glucose, the 
mean of the estimated values of regression was 2.11 mg/dL in the study population, 
and less than 95% of the population showed a regression to the mean of 5.99 mg/dL 
for a cut off point of 100 mg/dL, whereas for 110mg/dL the mean was 2.58 mg/dL. In 
the case of HbA1c, the mean of the estimated values of regression was 0.05% for both 
5.7% and 6% cut-off points, and less than 95% of the population showed a regression 
to the mean of 0.17%.
Factors associated with regression to normal glucose levels from prediabetes
Overall, rural Puno in comparison to highly urbanized Lima evidenced a regression 
trend in the crude models using WHO, ADA and NICE definitions evidenced by the 
level of association. However, in the adjusted model, this association did not remain 
significant. In the WHO definition model, none of the variables were associated with 
regression to normal glucose levels.
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Using the ADA definition, in the adjusted model, those in the highest vs. lowest tertile 
of the wealth index of socioeconomic status (0.65, 99.4% CI 0.46 – 0.92), those with 
insulin resistance (RRR 0.67, 99.4% CI 0.48 – 0.95), and those with obesity compared 
to participants with normal BMI (RRR 0.58, 99.4% CI 0.41 – 0.84) had lower probability 
to regress to normal glucose levels (Table 3).
According to NICE definition, participants aged with ≥45 years old in comparison to 
younger participants (RRR 0.79, 99.4% CI 0.63 – 0.99), and those with overweight or 
obesity (RRR 0.78, 99.4% CI 0.63 – 0.95), in comparison to those with normal BMI, 
had lower probability to regress to normal glucose levels.
Factors associated with progression from prediabetes to diabetes 
Using ADA definition, rural Puno in comparison to Lima was associated to less 
progression to diabetes in the crude analysis, but not in the adjusted model. Other 
factor like insulin resistance (RRR 1.79, 99.4% CI 1.07 – 2.99) was associated with 
higher probability to progress to diabetes in the adjusted model.
According to NICE definition, insulin resistance and obesity in comparison to normal 
BMI was associated to higher probability to progress to diabetes in the crude analysis. 





Given that most of the attention on the clinical side appears to focus on progression 
towards disease, the findings of regression to normal glucose levels is equally or more 
important to signal avenues for prevention and feasible targets to sustain public health 
efforts. The prevalence of prediabetes, as well as estimates of regression to normal 
glucose levels and, progression towards T2DM differed widely between definitions by 
WHO, ADA and IEC or NICE. Similarly, the factors associated with the probability to 
regress to normal glucose levels in comparison to maintain prediabetes status or 
progress to T2DM among the study sample differed according to the different criteria. 
Overall, older age, high wealth index, hypertension, insulin resistance, and having a 
BMI ≥25 were associated with lower probability to regress to normal glucose levels. 
On the other hand, insulin resistance and having a BMI ≥30, were associated with 
greater probability to progress to diabetes. Furthermore, our additional analyses 
showed that the contribution of regression to the mean was negligible, providing 
additional strength to our estimations.
Comparison with other studies
The prevalence of impaired fasting glucose in this sample varies widely between 5.6% 
and 49.5%. This problem was found in other countries, where the change of the 
prediabetes criteria increased its prevalence up to 37% (28, 29) and 50% in China (26) 
when either elevated fasting plasma glucose or borderline raised levels of HbA1c were 
considered as part of the diagnosis. In the U.S., where HbA1c is part of the prediabetes 
criteria, the annual risk for developing T2DM among adults with self-report diagnosis 
of prediabetes is around 2% (28, 29). In the Diabetes Prevention Program Study, 
based on impaired fasting glucose (95-125 mg/dl) and impaired glucose tolerance 
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(140-199 mg/dl after two hours of oral ingestion of 75-gr glucose), the annual risk to 
develop diabetes ranged between 5-11% in the placebo group (30). 
Regression from prediabetes to normal glucose levels values was between 31.4% and 
66.9% according to each definition. One factor related to regression to normal glucose 
levels in the crude analysis was study site; for instance, individuals from Tumbes had 
lower probability to regress and those from rural Puno had higher probability to regress 
in comparison to Lima. Our findings show that site could be risk factor associated to 
regressing to normal glucose levels, highlighting that lifestyle (physical activity, diet, 
between others) may account for these differences. Site may also signal the need for 
adequate surveillance efforts able to capture such subtleties, important for larger 
society-wide diabetes prevention efforts.
Also, lifestyle behaviors varied in urban and rural areas and, for instance, the 
progression towards T2DM differed in different population groups (31). High altitude 
can be another factor facilitating the regression to normal glucose levels. Thus, there 
is some evidence that glucose levels in high altitude is lower than at sea level (32), 
and this could be explained by the increase of insulin receptor levels (33, 34).
Insulin resistance at baseline was a variable associated with reduced probability of 
regressing to normal glucose levels. Previous studies found association with greater 
insulin secretion (15), higher β-cell function and insulin sensitivity (16), all this could 
explain the pathophysiological mechanisms that can partly support our findings. 
Other factors like sex, educational level, daily smoking, hazardous drinking, physical 
activity levels or family history of T2DM were not associated in the crude analysis. A 
previous study found association between female sex and regression to normal 
glucose levels (16), whereas other studies did not (14, 15). However, a study reported 
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that women had higher index of insulin secretion compared to men (35). Regarding 
smoking, a study found that those who never smoked or were former smoker had 
higher probability of regressing to normal glucose levels compared to current smokers 
(14).
Regarding BMI, and using ADA and NICE definition, participants with overweight had 
lower probability to regress to normal glucose levels as reported by previous studies 
analyzing this variable as categorical and continuous (14, 16). Similarly, it has been 
described that weight loss (15) and percentage weight change were associated to 
regression to normal glucose levels (16).
Progression from pre-diabetes to diabetes
Progression towards T2DM in participants with prediabetes was 8.5% using ADA, 
9.4% using NICE and 28.8% using WHO definition at 2.2 years, when the criteria for 
prediabetes and diabetes were used according to each definition. A meta-analysis 
evaluated the T2DM incidence according to different glucose disorders definitions as 
exposure (impaired fasting glucose cut-offs recommended by the ADA and WHO and 
raised HbA1c defined by IEC) and the outcome was any criteria of diagnosis of T2DM 
(7). The incidence rates of T2DM per 1000 person-year were 35.5 using ADA (only 
considering glucose), 35.6 using IEC, and 47.4 using WHO definition. Their findings 
also suggest that IEC definition slightly overestimate the risk of developing T2DM 
compared to WHO cut-offs for impaired fasting glucose and impaired glucose 
tolerance. Nevertheless, the results of this meta-analysis must be interpreted 
cautiously because the T2DM definition was not analyzed in subgroups according to 
the prediabetes definition used. A recent study conducted in Brazil among active or 
retired civil servants from public universities and research institutes compared five 
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definitions of hyperglycemia using glucose and HbA1c (glucose levels according WHO 
and ADA, 2-hr plasma glucose, HbA1c according to ADA and IEC) to estimate risk of 
progression to type 2 diabetes over 3.7 years. They found that glucose levels based 
in WHO criteria and 2-hr plasma glucose predict progression to diabetes better than 
the other definitions, however in general sensitivity to predict progression was low (36). 
Our study amplifies these observations by studying general populations from different 
sites across the spectrum of rural and urban settings. Our study findings also point to 
the need for population-based strategies to prevent diabetes rather than focusing on 
screen-and-test approaches. "
Regarding factors related to progression to diabetes, a previous study in United States 
with patients enrolled in Medicaid found that older age, hypertension, obesity and 
dyslipidemia were associated to progression to diabetes (37). Compared to our 
results, obesity was associated with progression to T2DM depending upon the 
prediabetes definition used. An interesting factor associated to greater progression to 
diabetes in the crude analysis was consumption of ≥ 5 portions of fruits and vegetables 
a day. According to the literature, fruits and vegetables consumption is recommended 
for preventing type 2 diabetes and other conditions. However, some controversial 
results were reported in previous studies related to the effect of fruits and vegetables 
in the prevention of diabetes (38, 39); thus, a recent study assessing the effect of 
different type of fruits found heterogeneity in the association of diabetes progression 
between different types of fruits -greater consumption of grapes and apples lower risk 
of type 2 diabetes, whereas greater consumption of sweet melon and fruit juice is 
associated to higher risk (40). Then, it is important to know the type of fruits and 
vegetables people consumed and their relation with type 2 diabetes in order to provide 
better recommendations.  
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Relevance to public health
Previous studies found that different definitions of prediabetes can raise its prevalence 
up to 50% (26). Taking into account that less than 10% might progress towards T2DM, 
a strategy to reduce this risk among individuals with prediabetes would impact with 
extra costs to the health system. A systematic review found that screening and 
treatment strategies to prevent T2DM had limitations because even when 
interventions lasting from 6 months up to 7 years may delay the onset of T2DM, many 
individuals could be incorrectly classified as having prediabetes (41). For these 
reasons experts say that screening and treating people can be effective for a few 
patients but any effort to combat the rise in T2DM will require a “massive” response 
that goes well beyond screening individual people (41).
Also, we identified that most of the participants regress to normal glucose levels or 
maintain prediabetes status, while a small proportion progress to T2DM. The 
identification of factors associated with regression to normal glucose levels and 
progression to type 2 diabetes would allow clinicians to have appropriate tools to 
improve clinical practice, classifying individuals with prediabetes according to their risk 
and implementing adequate intervention strategies.
Strengths and Limitations
This study compares the three different definitions of prediabetes in a population from 
Latin America, benefiting from a population-based approach with random sampling 
across a diversity of geographical scenarios. In 2017, a systematic review that 
searched for studies of prediabetes screening did not include studies from Latin 
America countries (26). In addition, our study complemented its approach with a sound 
22
methodological approach to evaluate the potential effects of regression to the mean 
on our estimates.
However, this study has some limitations. First, 19% of participants were lost to follow-
up or were not included in this follow-up analysis, and most of them were from rural 
areas, low socioeconomic status and lower educational levels (Supplemental material 
1), which may have a differential effect on our findings. Second, we did not perform 
oral glucose tolerance test, and it is known that risk and intervention effectiveness 
differs by prediabetes phenotype, e.g. the effectiveness of lifestyle preventive 
interventions is dissimilar in those with impaired fasting glucose and in those with 
impaired glucose tolerance, so they need different preventive interventions (42). Third, 
2.2 years can be considered a short follow-up period, so these results could be 
considered preliminary observations of a condition, yet the study sample afforded 
sufficient number of cases to study regression from prediabetes to normal glucose 
levels. Fourth, the length of time individuals had prediabetes at baseline was not 
known; and previous findings from the Whitehall Study (43) indicate that the trajectory 
to the development of T2DM can be as long as 13 years. Hence, the ability of 
participants to progress or regress over the 2.2 years may have been influenced by 
baseline beta cell function. Finally, diet patterns were not included as confounder and 
only a proxy of this, i.e. fruit and vegetables intake, was analyzed. In addition, physical 
activity was measured using validated questionnaires (i.e. working-related and leisure 
time physical activity levels of the IPAQ) instead of more objective measurements. 
Regression to the mean may be present; this theory states that with time some 
changes are consequence of a process of learning or a tendency. However, we 
explored this effect using the formula of Barnett AG et al (27) and we confirmed that 
the regression to the mean effect was negligible. 
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Conclusion
The prevalence of prediabetes, and its transition to different stages over time, differs 
widely between assessed definitions. The magnitude of regression to normal glucose 
levels is much higher than progression towards T2DM, which provide a unique 
understanding of prediabetes in Peru and probably in others LMIC settings. Among 
individuals with prediabetes, factors associated to regression to normal glucose levels 
were age, wealth index, hypertension, insulin resistance, and BMI. Also, the factors 
associated to progression to diabetes were age, insulin resistance and BMI.
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Table 1. Definitions for the exposure and outcomes of the current study
Normal glucose 
levels
Prediabetes Type 2 Diabetes





FPG ≥126 mg/dL 
(>= 7 mmol/L)
ADA FPG<100 mg/dL 









FPG ≥126 mg/dL 
(≥7 mmol/L) or 
HbA1c ≥6.5% 
(53 mmol/mol)







FPG: Fasting Plasma glucose. HbA1c: Glycated hemoglobin
WHO: World Health Organization, ADA: American Diabetes Association, IEC: International 
Excellence Committee, NICE: National Institute for Health and Clinical Excellence.
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Table 2. Progression to type 2 diabetes mellitus and regression to normal glucose levels
Follow-up 
Baseline N=2345 Normal Prediabetes Diabetes
WHO    
       Normal 2192 1967 (89.7%) 149 (6.8%) 76 (3.5%)
       Prediabetes 153 76 (49.7%) 33 (21.6%) 44 (28.8%)
ADA (glucose + A1c)     
      Normal 1088 708 (65.1%) 355 (32.6%) 25 (2.3%)
      Prediabetes 1257 395 (31.4%) 744 (59.2%) 118 (9.4%)
IEC/NICE     
      Normal 1768 1566 (88.6%) 108 (6.1%) 94 (5.3%)
      Prediabetes 577 386 (66.9%) 142 (24.6%) 49 (8.5%)
WHO: World Health Organization, ADA: American Diabetes Association, IEC: International 
Excellence Committee, NICE: National Institute for Health and Clinical Excellence
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Table 3. Regression to normal glucose levels in participants with impaired fasting glucose or pre-diabetes
Normal glucose levels (WHO)
N= 153
Normal glucose levels (ADA)
N= 1 256
Normal glucose levels (IEC/NICE)
N= 577 
Crude Adjusted Crude Adjusted Crude Adjusted 
RR(95% CI) RR(99.4% CI) RR(95% CI) RR(99.4% CI) RR(95% CI) RR(99.4% CI)
Study setting
Lima REF REF REF REF REF REF
Urban Puno 1.02 (0.66 - 1.57) 0.99 (0.52 – 1.87) 1.07 (0.82 - 1.39) 0.97 (0.67 – 1.39) 1.23 (1.02 - 1.48) 1.15 (0.89 – 1.49)
Rural Puno 1.58 (1.11 - 2.25) 1.15 (0.57 – 2.30) 1.88 (1.51 - 2.35) 1.20 (0.85 – 1.70) 1.56 (1.33 - 1.83) 1.29 (0.99 – 1.68)
Tumbes 0.68 (0.46 - 1.01) 0.64 (0.37 – 1.09) 1.06 (0.85 - 1.31) 0.94 (0.69 – 1.27) 1.20 (1.01 - 1.42) 1.10 (0.87 – 1.39)
Sex
Female REF REF REF REF REF REF
Male 1.21 (0.89 - 1.67) 1.19 (0.74 – 1.92) 1.13 (0.96 - 1.33) 1.06 (0.84 – 1.32) 1.04 (0.93 - 1.16) 0.97 (0.83 – 1.12)
Age
35 - 44 years REF REF REF REF REF REF
45 – 54 years 1.05 (0.62 – 1.77) 1.12 (0.50 – 2.50) 0.91 (0.72 – 1.14) 0.91 (0.67 – 1.25) 0.84 (0.71 – 0.99) 0.79 (0.63 – 0.99)*
55-64 years 0.95 (0.57 – 1.59) 0.99 (0.47 – 2.07) 0.78 (0.61 – 0.98) 0.79 (0.58 – 1.09) 0.86 (0.73 – 1.01) 0.81 (0.65 – 1.01)
≥ 65 years 1.20 (0.72 – 2.02) 1.28 (0.59 – 2.75) 0.83 (0.65 – 1.04) 0.72 (0.51 – 1.02) 0.94 (0.81 – 1.09) 0.81 (0.65 – 1.01)
Education level
< 7 years REF REF REF REF REF REF
7 – 11 years 1.06 (0.73 - 1.53)  - 1.04 (0.86 - 1.25)  - 1.01 (0.89 - 1.15)  -
12+ years 0.96 (0.63 - 1.45)  - 0.89 (0.71 - 1.11)  - 0.97 (0.83 - 1.12)  -
Socioeconomic 
status
Lowest tertile REF REF REF REF REF REF
Middle tertile 1.16 (0.75 - 1.83) 1.44 (0.74 – 2.78) 0.83 (0.69 - 0.99) 0.94 (0.78 – 1.14) 0.90 (0.80 - 1.01) 1.05 (0.87 – 1.26)
Highest tertile 0.86 (0.54 - 1.38) 0.92 (0.45 – 1.89) 0.53 (0.43 - 0.66) 0.65 (0.46 – 0.92)* 0.76 (0.67 - 0.88) 0.92 (0.74 – 1.14)
Family history of 
diabetes
2
No REF REF REF REF REF REF
Yes 0.65 (0.31 - 1.35) - 0.91 (0.65 - 1.27) - 0.90 (0.70 - 1.15) -
Hypertension
No REF REF REF REF REF REF
Yes 0.91 (0.62 - 1.33) 0.82 (0.48 – 1.39) 0.66 (0.52 - 0.83) 0.80 (0.57 – 1.13) 0.92 (0.81 - 1.05) 1.01 (0.82 – 1.23)
Insulin resistance
No REF REF REF REF REF REF
Yes 0.80 (0.58 - 1.11) 1.01 (0.65 – 1.60) 0.50 (0.40 - 0.63) 0.67 (0.48 – 0.95)* 0.72 (0.62 - 0.82) 0.80 (0.65 – 0.99)*
Physical activity
Low REF REF REF REF REF REF
Moderate/high 1.12 (0.79 - 1.58)  - 1.10 (0.92 - 1.31)  - 1.08 (0.96 - 1.23)  -
Body mass index
<25 kg/m2) REF REF REF REF REF REF
≥25 and <30 kg/m2 0.68 (0.46 - 1.00) 0.79 (0.42 – 1.51) 0.69 (0.58 - 0.82) 0.80 (0.62 – 1.02) 0.79 (0.71 - 0.89) 0.85 (0.73 – 0.99)*
≥30 kg/m2 0.57 (0.40 - 0.81) 0.68 (0.34 – 1.34) 0.42 (0.34 - 0.53) 0.58 (0.41 – 0.84)* 0.66 (0.58 - 0.76) 0.78 (0.63 – 0.95)*
Hazardous drinking
No REF REF REF REF REF REF
Yes 0.91 (0.47 - 1.78)  - 1.03 (0.72 - 1.48)  - 0.93 (0.71 - 1.22)  -
Daily smoking
No REF REF REF REF REF REF
Yes 0.80 (0.27 - 2.38)  - 0.84 (0.52 - 1.38)  - 0.89 (0.64 - 1.26)  -
Fruits and 
vegetables
Less than 5 portions REF REF REF REF REF REF
5 or more portions 0.50 (0.09 - 2.75)  - 0.99 (0.64 - 1.54)  - 0.72 (0.47 - 1.09)  -
Bold 
* Bonferroni correction for p-value (p<0.006)
WHO: World Health Organization, ADA: American Diabetes Association, IEC: International Excellence Committee, NICE: National Institute for 
Health and Clinical Excellence
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Crude Adjusted Crude Adjusted Crude Adjusted 
RR(95% CI) RR(99.4% CI) RR(95% CI) RR(99.4% CI) RR(95% CI) RR(99.4% CI)
Study setting
Lima REF REF REF REF REF REF
Urban Puno 0.27 (0.07 – 1.08) 0.26 (0.07 – 1.00) 0.62 (0.37 – 1.05) 0.72 (0.34 – 1.52) 0.24 (0.07 – 0.79) 0.29 (0.05 – 1.61)
Rural Puno 0.39 (0.06 – 2.55) 0.42 (0.08 – 2.37) 0.29 (0.13 – 0.66) 0.42 (0.12 – 1.45) - -
Tumbes 1.08 (0.65 – 1.79) 1.06 (0.64 – 1.75) 0.78 (0.54 – 1.14) 0.87 (0.49 – 1.52) 0.51 (0.25 – 1.03) 0.64 (0.22 – 1.88)
Sex
Female REF REF REF REF REF REF
Male 0.89 (0.53 – 1.48) 0.99 (0.48 – 2.05) 0.85 (0.60 – 1.20) 1.06 (0.65 – 1.73) 0.89 (0.45 – 1.77) 1.18 (0.44 – 3.15)
Age
35 - 44 years REF REF REF REF REF REF
45 – 54 years 0.93 (0.46 – 1.92) 0.91 (0.32 – 2.54) 1.71 (0.97 – 3.02) 1.71 (0.79 – 3.77) 1.17 (0.42 – 3.24) 1.24 (0.30 – 5.17)
55-64 years 0.91 (0.46 – 1.79) 0.95 (0.37 – 2.45) 1.70 (0.98 – 2.98) 1.79 (0.82 – 3.88) 0.71 (0.24 – 2.10) 0.83 (0.19 – 3.52)
≥ 65 years 0.44 (0.16 – 1.17) 0.43 (0.09 – 1.97) 1.22 (0.67 – 2.22) 1.58 (0.66 – 3.80) 0.71 (0.24 – 2.10) 1.01 (0.22 – 4.73)
Education level
< 7 years REF REF REF REF REF REF
7 – 11 years 1.24 (0.71 – 2.17)  - 0.75 (0.50 – 1.12)  - 1.22 (0.58 – 2.58)  -
12+ years 0.91 (0.46 – 1.80)  - 0.84 (0.54 – 1.31)  - 0.75 (0.28 – 2.01)  -
Socioeconomic 
status
Lowest tertile REF REF REF REF REF REF
Middle tertile 0.86 (0.41 – 1.79) 0.55 (0.20 – 1.53) 1.22 (0.77 – 1.96) 0.87 (0.45 – 1.67) 2.00 (0.76 – 5.22) 1.01 (0.23 – 4.53)
Highest tertile 0.97 (0.49 – 1.90) 0.76 (0.28 – 2.10) 1.52 (0.98 – 2.35) 0.97 (0.50 – 1.88) 2.14 (0.84 – 5.48) 1.02 (0.24 – 4.35)
Family history of 
diabetes
4
No REF REF REF REF REF REF
Yes 1.18 (0.55 – 2.54) - 1.40 (0.80 – 2.45) - 1.92 (0.71 – 5.20) -
Hypertension
No REF REF REF REF REF REF
Yes 0.97 (0.55 – 1.74) 1.05 (0.58 – 1.94) 1.05 (0.70 - 1.57) 0.84 (0.47 – 1.51) 0.97 (0.44 – 2.11) 0.86 (0.25 – 2.92)
Insulin resistance
No REF REF REF REF REF REF
Yes 1.33 (0.74 – 2.40) 0.90 (0.49 – 1.64) 2.47 (1.75 – 3.47) 1.79 (1.07 – 2.99)* 2.89 (1.46 – 5.72) 1.79 (0.69 – 4.59)
Physical activity
Low REF REF REF REF REF REF
Moderate/high 1.23 (0.70 – 2.14)  - 0.80 (0.56 – 1.13)  - 0.84 (0.42 – 1.66)  -
Body mass index
<25 kg/m2) REF REF REF REF REF REF
≥25 and <30 kg/m2 1.11 (0.34 – 3.63) 1.03 (0.18 – 5.88) 1.45 (0.80 – 2.63) 1.16 (0.47 – 2.85) 3.64(0.83– 16.02) 2.49 (0.28 – 22.45)
≥30 kg/m2 2.01 (0.69 – 5.86) 1.58 (0.32 – 7.81) 3.17 (1.81 – 5.54) 1.98 (0.79 – 4.98) 5.76 (1.36 – 24.4) 2.72 (0.29 – 25.58)
Hazardous drinking
No REF REF REF REF REF REF
Yes 1.29 (0.56 – 2.95)  - 1.33 (0.68 – 2.61)  - 1.17 (0.29 – 4.70)  -
Daily smoking
No REF REF REF REF REF REF
Yes 1.41 (0.47 – 4.27)  - 1.19 (0.51 – 2.77)  - -  -
Fruits and 
vegetables
Less than 5 portions REF REF REF REF REF REF
5 or more portions 1.77 (0.64 – 4.90)  - 1.44 (0.67 – 3.10)  - 3.60 (1.38 – 9.39)  3.04 (0.77 – 12.02)
* Bonferroni correction (p<0.006)
WHO: World Health Organization, ADA: American Diabetes Association, IEC: International Excellence Committee, NICE: National Institute for 
Health and Clinical Excellence.
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Highlights
-  In this cohort study, we found that figures depended on the definitions used 
(WHO, ADA, NICE), but around half of those with pre-diabetes had normal glucose 
2.2 years later while around one fifth to one tenth had progressed to diabetes.
-  Factors associated with regression to normal glucose levels and 
progression to type 2 diabetes mellitus were age, study site, body mass index, and 
insulin resistance.
-  The identification of factors associated with regression and progression 
would allow clinicians to classified individuals with prediabetes according to their 
risk and, on a larger scale by implementing adequate intervention strategies.
